No easy way up

Why execution could be only way for Allergan to turn its stock around

A prolonged period of underperformance at Allergan plc (NYSE:AGN) has activists agitating for change, but there likely aren’t any quick fixes.

Looming competition and IP setbacks for key franchises, a mixed business development record and a handful of quarterly misses have plagued the company over the past three years, crushing investor sentiment and its shares.

Allergan’s stock has declined nearly 50% since peaking at $339.50 on July 28, 2015.

Read the full 679 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers